永安药业(002365) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of 52.37 million yuan for 2024, compared to a loss of 68.03 million yuan in the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be 19.83 million yuan, a significant improvement from a loss of 29.13 million yuan last year[3]. - Basic earnings per share are forecasted to be 0.1787 yuan, recovering from a loss of 0.2320 yuan per share in the previous year[3]. Operational Factors - The main reasons for the turnaround include stable operations with increased production and sales, and reduced impairment losses compared to the previous year[5]. Financial Reporting - The financial data presented is preliminary and subject to final audit in the annual report[4][6]. - The company emphasizes the importance of investor awareness regarding investment risks associated with the preliminary earnings forecast[7].